Introduction {#section1-1179299X17732007}
============

Purpose {#section2-1179299X17732007}
-------

The purpose of this study was to develop methods for improving salivary biomarker efficiencies in oral cancer screening with inferential tools adapted from clinical epidemiology and Bayesian analysis.

Problem {#section3-1179299X17732007}
-------

Even as screening and diagnostic technologies drop in price, methodological efficiencies can improve access and hasten implementation of salivary disease screening. Reducing test complexity, cost, and interpretation of results while increasing test information and robustness is a useful goal of any medical screening.

However, the current methods of biomarker discovery might limit their value in detecting disease. Potential salivary biomarkers are first observed as different concentrations in the saliva of healthy patients versus that of patients with cancer. From these samples, some or all of 4 attributes are commonly reported: sensitivities, specificities, areas under the curve (AUCs), and statistical significance in biomarker concentration between healthy and cancer groups.

However, from a clinical or policy decision's perspective, more information is needed than just these 4 statistics. First, sensitivity and specificity are test characteristics and not related to patient health status. Statistical significance is subject to misinterpretation and often fails to meet underlying assumptions.^[@bibr1-1179299X17732007]^ Finally, AUC is not easily computed and interpreted for use in medical decisions. Area under the curve may represent biomarker accuracy in a population but does not offer an estimate of personal risk given positive test results. However, the positive predictive value (PPV) includes test accuracy characteristics, accounts for disease prevalence, and states personal patient risk as a probability of having a disease.

Oral cancer {#section4-1179299X17732007}
-----------

Oral cancer is a significant disease worldwide with up to 400 000 new cases and almost 130 000 deaths annually.^[@bibr2-1179299X17732007]^ About 90% of oral cancers are oral squamous cell carcinoma (OSCC), and 80% occur in Southeast Asian countries. In the United States, the 5-year OSCC survival rate is 60%, but higher incidence and lower survival rates have been reported in some South Asian countries.^[@bibr3-1179299X17732007][@bibr4-1179299X17732007]--[@bibr5-1179299X17732007]^ Most OSCC lesions are small, asymptomatic, and easily overlooked or misjudged making early detection a challenge. Risk factors include alcohol and tobacco consumption, use of betel quid chew, and alcohol-based mouthwashes.^[@bibr6-1179299X17732007]^ More than 95% of those with OSCC smoke tobacco, drink alcohol, or both. In recent decades, more cases of OSCC are emerging without known attributable risk factors.^[@bibr7-1179299X17732007]^

Early detection of OSCC would improve survival, mortality, and morbidity. The gold standard for diagnosis is a biopsy of the suspicious lesion, but this test is not convenient for screening purposes because of its invasive nature, high cost, and need for specially trained medical personnel and equipment. However, saliva sampling to assess disease biomarkers is simple and less expensive, and multiple samples can be obtained for disease monitoring. Research suggests that salivary biomarkers have high discriminatory power for multiple diseases and cancers,^[@bibr8-1179299X17732007][@bibr9-1179299X17732007][@bibr10-1179299X17732007][@bibr11-1179299X17732007]--[@bibr12-1179299X17732007]^ and they have been well characterized and validated by comparisons of biomarker levels in healthy and cancerous oral epithelia. Development from normal to OSCC cells leads to altered expression of proteins and messenger RNA markers in saliva. As such, transcriptomic and proteomic approaches to biomarker development have had the most success in clinical testing.^[@bibr13-1179299X17732007]^

The most informative screening tests are both highly sensitive and specific.^[@bibr14-1179299X17732007]^ High *S*ensitivity with a *N*egative finding rules out disease, the SNout mnemonic. A highly *S*pecific test with a *P*ositive will rule-in disease, the SPin mnemonic. It may seem intuitive that more tests improve screening accuracy, but they do not, unless read as conditional probabilities where each biomarker test is read in context with others.

Independence of biomarker probabilities can only be incorrect because they are derived from the same biological system (person). For instance, 2 truly independent and positive cancer biomarkers (designated T+) in just 3% and 4% in healthy people would co-occur at just 0.12% (3% × 4%) in healthy individuals. The simultaneous occurrence of such rare biomarkers is prima facie support of a nonhealthy state, but such evidence neglects disease prevalence and does not indicate the personal risk of disease for the screened individual with both biomarkers.

Likelihood ratios reveal biomarker information values {#section5-1179299X17732007}
-----------------------------------------------------

The likelihood ratio (LR) describes a medical test's information value. A biomarker's ratio of true hit rate to false positive rate, is a positive LR. LR is used in signal detection research,^[@bibr14-1179299X17732007],[@bibr15-1179299X17732007]^ with analogous application to cancer detection. The LR is an index of how well a biomarker can separate the signal from noise.

Each biomarker offers information about the presence or absence of a disease state with varying degrees of accuracy. This task is similar to that of psychological testing, where each test item reflects the extent of an underlying construct, generally called θ. With cancer as θ, biomarker LRs can improve screening accuracy with fewer biomarker items, i.e., improve screening efficiency.

Bayes factors as evidential support {#section6-1179299X17732007}
-----------------------------------

Bayes factors (BF) estimate a biomarker's strength of evidence or evidential support (ES).^[@bibr15-1179299X17732007][@bibr16-1179299X17732007]--[@bibr17-1179299X17732007]^ Mathematically, the BF is the ratio of probability of data occurring with and without a specific biomarker. Evidential support, the natural logarithm of the BF, expresses the contribution to screening information provided by the biomarker.^[@bibr15-1179299X17732007]^

Correcting for inflated personal risk, PPV {#section7-1179299X17732007}
------------------------------------------

[Figure 1](#fig1-1179299X17732007){ref-type="fig"} illustrates the effects of prevalence on PPV under 6 hypothetical biomarkers, each of a different fixed sensitivity and specificity. The biomarker on the red line has 90% sensitivity and 90% specificity. Other lines in [Figure 1](#fig1-1179299X17732007){ref-type="fig"} represent different combinations of sensitivity and specificity. In all cases, PPV increases with prevalence. For prevalence under 20% (an exaggerated maximum for disease prevalence), the 6 combinations of sensitivities and specificities show wide discrepancies in PPV. Therefore, all retrospective case-control studies in which 50% of cases have cancer and the other 50% are without cancer (and presumably healthy) inflate PPV estimates. In terms of sensitivity and specificity, some degree of each are required to improve up on prevalence as the a priori best estimate of personal cancer status.

![The effects of prevalence on positive predictive value (PPV): simulations comparing 6 sensitivity and specificity combinations.](10.1177_1179299X17732007-fig1){#fig1-1179299X17732007}

Materials and Methods {#section8-1179299X17732007}
=====================

Studies chosen {#section9-1179299X17732007}
--------------

The authors selected 137 analyses with keywords---biomarkers, oral cancer, oral squamous cell carcinoma, sensitivity, and specificity---in 16 papers from a total of 80 reviewed.^[@bibr3-1179299X17732007],[@bibr4-1179299X17732007],[@bibr7-1179299X17732007],[@bibr11-1179299X17732007][@bibr12-1179299X17732007]--[@bibr13-1179299X17732007],[@bibr16-1179299X17732007][@bibr17-1179299X17732007][@bibr18-1179299X17732007][@bibr19-1179299X17732007][@bibr20-1179299X17732007][@bibr21-1179299X17732007][@bibr22-1179299X17732007][@bibr23-1179299X17732007][@bibr24-1179299X17732007][@bibr25-1179299X17732007][@bibr26-1179299X17732007][@bibr27-1179299X17732007][@bibr28-1179299X17732007][@bibr29-1179299X17732007][@bibr30-1179299X17732007][@bibr31-1179299X17732007][@bibr32-1179299X17732007][@bibr33-1179299X17732007][@bibr34-1179299X17732007][@bibr35-1179299X17732007][@bibr36-1179299X17732007][@bibr37-1179299X17732007][@bibr38-1179299X17732007][@bibr39-1179299X17732007][@bibr40-1179299X17732007][@bibr41-1179299X17732007][@bibr42-1179299X17732007][@bibr43-1179299X17732007][@bibr44-1179299X17732007][@bibr45-1179299X17732007][@bibr46-1179299X17732007][@bibr47-1179299X17732007][@bibr48-1179299X17732007][@bibr49-1179299X17732007][@bibr50-1179299X17732007][@bibr51-1179299X17732007][@bibr52-1179299X17732007][@bibr53-1179299X17732007][@bibr54-1179299X17732007][@bibr55-1179299X17732007][@bibr56-1179299X17732007][@bibr57-1179299X17732007][@bibr58-1179299X17732007][@bibr59-1179299X17732007][@bibr60-1179299X17732007][@bibr61-1179299X17732007][@bibr62-1179299X17732007][@bibr63-1179299X17732007][@bibr64-1179299X17732007][@bibr65-1179299X17732007][@bibr66-1179299X17732007][@bibr67-1179299X17732007][@bibr68-1179299X17732007][@bibr69-1179299X17732007][@bibr70-1179299X17732007][@bibr71-1179299X17732007][@bibr72-1179299X17732007][@bibr73-1179299X17732007][@bibr74-1179299X17732007][@bibr75-1179299X17732007][@bibr76-1179299X17732007][@bibr77-1179299X17732007][@bibr78-1179299X17732007][@bibr79-1179299X17732007][@bibr80-1179299X17732007][@bibr81-1179299X17732007][@bibr82-1179299X17732007][@bibr83-1179299X17732007][@bibr84-1179299X17732007][@bibr85-1179299X17732007]--[@bibr86-1179299X17732007]^ All studies were chosen from searches in PubMed and Web of Knowledge databases in 2014. Accepted papers reported at least 2 separate estimates of sensitivity, specificity, AUC, or statistical significances between diseased and healthy groups for each biomarker. Two biomarker parameter estimates allow some degree of reliability for analysis. Twenty-six biomarkers met the criteria.

The final 26 selected biomarkers and associated panels are summarized in [Appendix 1](#table2-1179299X17732007){ref-type="table"}. Outcomes were transferred to Meta-DiSc and R language for computation of LRs. Biomarkers selected were: absent in melanoma 1 (AIM1), calcitonin-related polypeptide alpha (CALCA), cyclin-A1 (CCNA1), cyclin-D2 (CCND2), cadherin-1 (CDH1), death-associated protein (DAPK), deleted in colorectal carcinoma (DCC), erythrocyte sedimentation rate (ESR), hypermethylated in cancer 1 (HIC1), homeobox protein Hox-A9 (HOXA9), interleukin 1B (IL1B), interleukin 8 (IL8), O-6-methylguanine-DNA methyltransferase (MGMT), munc-18-interacting 1 (MINT1), munc-18-interacting 31 (MINT3), miR31, OAX1, p16, protein gene product 9.5 (PGP9.5), retinoic acid receptor beta (RARB), Ras association domain-containing protein 1 (RASSF1A), RNA-binding motif protein 6 (RBM6), retinoblastoma-interacting zinc-finger protein 1 (RIZ1), S100A2, sulfate adenylyltransferase (SAT), transforming growth factor beta receptor 2 (TBFBR2), and metalloproteinase inhibitor 3 (TIMP3).

Evidential support and likelihood ratio calculations {#section10-1179299X17732007}
----------------------------------------------------

Probabilities of data under the biomarker absent (or "null") condition over the biomarker present probability of data were obtained via an hierarchical data analytic approach described elsewhere.^[@bibr89-1179299X17732007],[@bibr90-1179299X17732007]^ The ratios are Bayes Factors; the logarithms of these ratios express the ES's. In a sense, the BF is a "between" condition likelihood ratio, addressing how much more information is provided by a biomarker's presence versus its absence.

The complement is a "within" index, the LR describes biomarker accuracy or efficiency. LR is the ratio of true positives to false positives. LR times prevalence in odds form yields a PPV in odds form. LR was then adjusted for sample prevalence in case-control studies by dividing by prevalence to obtain an unbiased LR. Biomarker diagnostic accuracy was visualized using the "mada" package in R as shown in [Figure 2](#fig2-1179299X17732007){ref-type="fig"}.^[@bibr91-1179299X17732007]-93^

![Biomarkers equal better test efficiencies with fewer versus more biomarkers---illustration that fewer biomarkers can have a higher positive predictive value and decreased error variance. Fewer number of biomarkers on the right (B) have a higher discriminating ability measured in area under the curve, AUC = 0.818, than the more complex "scattershot" approach on the left (A), where the AUC = 0.760.](10.1177_1179299X17732007-fig2){#fig2-1179299X17732007}

Results {#section11-1179299X17732007}
=======

[Table 1](#table1-1179299X17732007){ref-type="table"} presents the 26 selected biomarkers from the 16 accepted studies listed individually and in panels with associated sensitivities (Se), specificities (Sp), AUCs, or statistical significance in biomarker amount between healthy individuals and patients with OSCC. The 5 most sensitive biomarkers were CALCA (Se = 1.00), RBM6 (0.97), S100A2 (0.96), HOXA9 (0.81), and IL8 (0.74). The 5 most specific biomarkers were RASSF1A (Sp = 0.993), AIM1 (0.991), ESR (0.986), p16 (0.950), and DCC (also 0.950). In [Figure 2](#fig2-1179299X17732007){ref-type="fig"} (scatterplot), all OSCC biomarkers and panels reviewed in the current evidence synthesis are plotted as AUCs for detecting OSCC. The scatterplot in [Figure 2A](#fig2-1179299X17732007){ref-type="fig"}, based on 137 data points of 26 biomarkers, has an AUC of 0.760. The 9 most informative LR biomarkers in [Figure 2B](#fig2-1179299X17732007){ref-type="fig"} have an AUC of 0.818.

###### 

Summary accuracy statistics for 26 oral salivary biomarkers.

![](10.1177_1179299X17732007-table1)

  Biomarkers   Name                                               References                                                                                                                                                                                                           Patients with OSCC   Patients without OSCC   Total no. of patients   Prevalence in case-control   No. of comparisons   Sensitivity           Specificity           AUC     LR (95% CI)         Evidential support   Evidence interpretation   LR+ rank
  ------------ -------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ----------------------- ----------------------- ---------------------------- -------------------- --------------------- --------------------- ------- ------------------- -------------------- ------------------------- ----------
  AIM1         Absent in melanoma                                 Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          187                  228                     415                     0.451                        4                    0.203(0.174--0.233)   0.991(0.985--0.997)   0.945   6.98(2.81--17.31)   −3.361               Strong                    2
  CALCA        Calcitonin-related polypeptide α                   Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          70                   50                      120                     0.592                        2                    1.000(1.000--1.000)   0.140(0.091--0.189)   0.976   1.17(0.91--1.50)    −3.191               Strong                    22
  CCNA1        Cyclin-Al                                          Carvalho et al,^[@bibr33-1179299X17732007]^Carvalho et al,^[@bibr63-1179299X17732007]^Demokan et al,^[@bibr50-1179299X17732007]^                                                                                     3811                 9264                    13 075                  0.291                        25                   0.304(0.297--0.312)   0.942(0.939--0.944)   0.737   5.13(4.31--6.12)    −1.956               Moderate                  6
  CCND2        Cyclin-D2                                          Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          621                  2357                    2978                    0.209                        13                   0.475(0.455--0.495)   0.756(0.747--0.765)   0.734   2.36(1.77--3.16)    −1.031               Weak                      16
  CDH1         Cadherin-1                                         Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          451                  1773                    2224                    0.203                        8                    0.692(0.670--0.714)   0.561(0.549--0.573)   0.624   1.43(1.07--1.91)    −1.055               Weak                      21
  DAPK         Death-associated protein                           Carvalho et al,^[@bibr33-1179299X17732007]^Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                               2281                 5605                    7886                    0.289                        13                   0.320(0.310--0.329)   0.933(0.930--0.936)   0.903   4.61(3.73--5.69)    −1.880               Moderate                  9
  DCC          Deleted in colorectal carcinoma                    Carvalho et al,^[@bibr33-1179299X17732007]^Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                               2438                 6009                    8447                    0.289                        15                   0.334(0.324--0.343)   0.950(0.947--0.952)   0.880   6.20(4.61--8.33)    −2.245               Moderate                  3
  ESR          Erythrocyte sedimentation rate                     Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          119                  278                     397                     0.300                        4                    0.370(0.325--0.414)   0.986(0.978--0.993)   0.975   7.66(2.15--27.34)   −3.694               Strong                    1
  HIC1         Hypermethylated in cancer 1                        Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          1007                 4455                    5462                    0.184                        22                   0.602(0.586--0.617)   0.730(0.724--0.737)   0.690   2.19(1.77--2.70)    −1.410               Weak                      18
  HOXA9        Homeobox protein Hox-A9                            Guererro-Preston et al,^[@bibr67-1179299X17732007]^                                                                                                                                                                  16                   16                      32                      0.500                        4                    0.813(0.715--0.910)   0.875(0.792--0.958)   0.750   2.28(1.10--4.69)    −3.412               Strong                    17
  IL1B         Interleukin 1B                                     Brinkmann et al,^[@bibr12-1179299X17732007]^Brinkmann et al,^[@bibr62-1179299X17732007]^Elashoff et al,^[@bibr74-1179299X17732007]^Li et al,^[@bibr22-1179299X17732007]^                                             361                  469                     830                     0.435                        11                   0.723(0.699--0.747)   0.797(0.779--0.816)   0.796   3.09(2.43--3.92)    −2.330               Moderate                  13
  IL8          Interleukin 8                                      Brinkmann et al,^[@bibr12-1179299X17732007]^Brinkmann et al,^[@bibr62-1179299X17732007]^Elashoff et al,^[@bibr74-1179299X17732007]^Li et al,^[@bibr22-1179299X17732007]^St John et al,^[@bibr23-1179299X17732007]^   459                  619                     1078                    0.426                        14                   0.736(0.716--0.757)   0.787(0.770--0.803)   0.832   3.27(2.49--4.29)    −2.333               Moderate                  12
  MGMT         0-6-methylguanine-DNA methyltransferase            Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          795                  1438                    2233                    0.356                        6                    0.297(0.281--0.313)   0.917(0.909--0.924)   0.792   3.32(2.73--4.05)    −1.534               Moderate                  11
  MINT1        Munc-18-interacting 1                              Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          780                  1679                    2459                    0.317                        7                    0.400(0.382--0.418)   0.887(0.869--0.885)   0.832   4.11(1.94--8.71)    −1.562               Moderate                  10
  MINT31       Munc-18-interacting 31                             Carvalho et al,^[@bibr33-1179299X17732007]^Carvalho et al,^[@bibr63-1179299X17732007]^Demokan et al,^[@bibr50-1179299X17732007]^                                                                                     2596                 6000                    8596                    0.302                        17                   0.285(0.276--0.294)   0.949(0.947--0.952)   0.658   5.10(4.15--6.28)    −2.009               Moderate                  7
  miR31        miR31                                              Liu et al,^[@bibr78-1179299X17732007]^                                                                                                                                                                               55                   48                      103                     0.534                        2                    0.655(0.590--0.719)   0.333(0.265--0.401)   0.172   0.49(0.01--21.21)   0.054                No evidence               27
  OAZ1         Ornithine decarboxylase antizyme 1                 Elashoff et al,^[@bibr74-1179299X17732007]^Li et al,^[@bibr22-1179299X17732007]^                                                                                                                                                                                                                                                                                                                                                                                   
  p16          p16                                                Carvalho et al,^[@bibr33-1179299X17732007]^Carvalho et al,^[@bibr63-1179299X17732007]^Demokan at al,^[@bibr50-1179299X17732007]^                                                                                     2790                 6560                    9350                    0.298                        18                   0.258(0.250--0.266)   0.950(0.947--0.953)   0.627   4.68(4.07--5.37)    −1.892               Moderate                  8
  PGP9.5       Protein gene product 9.5                           Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          630                  2516                    3146                    0.200                        15                   0.640(0.622--0.660)   0.654(0.645--0.664)   0.725   1.91(1.55--2.35)    −1.218               Weak                      19
  RARB         Retinoic acid receptor β                           Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          101                  205                     306                     0.330                        3                    0.693(0.647--0.739)   0.917(0.898--0.936)   0.784   5.38(0.33--88.33)   −3.218               Strong                    5
  RASSF1A      Ras association domain-containing protein 1        Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          88                   139                     227                     0.388                        2                    0.114(0.80--0.147)    0.993(0.986--1.000)   0.141   6.07(1.74--21.13)   −2.873               Strong                    4
  RBM6         RNA-binding motif protein 6                        Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          88                   53                      141                     0.624                        2                    0.977(0.961--0.993)   0.075(0.039--0.112)   0.957   1.10(0.77--1.58)    −1.256               Weak                      23
  RIZ1         Retinoblastoma-interacting zinc-finger protein 1   Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          88                   53                      141                     0.624                        2                    0.064(0.041--0.095)   0.925(0.888--0.961)   0.161   0.83(0.28--2.42)    0.109                No evidence               26
  S100A2       S100A2                                             Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          88                   47                      135                     0.652                        2                    0.955(0.932--0.977)   0.128(0.079--0.176)   0.617   1.10(0.97--1.26)    −1.123               Weak                      24
  SAT          Sulfate adenylyltransferase                        Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          369                  482                     851                     0.434                        11                   0.726(0.703--0.749)   0.768(0.748--0.787)   0.617   2.97(2.23--3.96)    −2.171               Moderate                  14
  TGFBR2       Transforming growth factor β receptor 2            Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          367                  1081                    1448                    0.253                        10                   0.589(0.563--0.614)   0.800(0.788--0.812)   0.682   1.87(1.39--2.52)    −1.745               Moderate                  20
  TIMP3        Metalloproteinase inhibitor 3                      Carvalho et al,^[@bibr63-1179299X17732007]^                                                                                                                                                                          972                  3542                    4514                    0.215                        15                   0.555(0.539--0.570)   0.761(0.753--0.768)   0.735   2.53(1.69--3.26)    −1.375               Weak                      15

OAZ1 was used only in combination with other biomarkers, so unique value of its contribution could not be calculated.

Information value (LR) and PPV {#section12-1179299X17732007}
------------------------------

The 5 highest LRs from reviewed studies were ESR (LR = 7.66), AIM1 (6.98), DCC (6.20), RASSFIA (6.07), and RARB (5.38). When reading biomarkers conditionally from lowest to highest LR that have prevalence levels of 2%, 0.2%, 0.02%, 0.002%, 0.0002%, the number of biomarkers needed to achieve a PPV 100% were 11, 14, 15, 16, 18, and 20, respectively (see [Figure 3](#fig3-1179299X17732007){ref-type="fig"}). In [Figure 3](#fig3-1179299X17732007){ref-type="fig"}, the dotted line shows the number of biomarkers plotted against the PPV on the *y* axis using conditional probabilities, with green area representing 95% confidence bands needed to screen for OSCC. The blue area and long dashed line represent the Youden index plot and the pink area and solid line represent the AUC analysis. Both the Youden and AUC plots are the number of biomarkers required to approach a PPV of 100%.

![Number of biomarkers needed to approximate a positive predictive value of 1.00. Rows represent example prevalences with 2% at the top, decreased by a factor of 0.1 to 0.0002% prevalence at the bottom row.](10.1177_1179299X17732007-fig3){#fig3-1179299X17732007}

By ordering from highest to lowest LR, the required number of biomarkers required to approach a PPV 100% for prevalence levels of 2%, 0.2%, 0.02%, 0.002%, and 0.0002% were 5, 8, 9, 11 and 12, respectively. Area under the curve appears to be more efficient than the LR conditional approach because it nears a PPV of 100% by starting with a high LR biomarker. For all sample prevalence conditions, 8 fewer biomarkers were needed to achieve the same OSCC screening accuracy. When the 4 least informative LR biomarkers are omitted from analysis, the number of biomarkers needed to achieve a PPV near 1.00 drops further to 3, 5, 7, 8, and 10 for each prevalence level.

The AUC and Youden index do not improve PPV by adding biomarkers. The Youden index is asymptotic at PPV = 25%, representing uncertainty for 75% of patients screened. Area under the curve was similar by increasing uncertainty: maximum screening accuracy achieved as PPV was 75%, leaving 25% error or uncertainty.

ES results {#section13-1179299X17732007}
----------

Six biomarkers showed strong ES: ESR (−3.694), AIM1 (−3.361), CALCA (−3.191), HOXA9 (−3.412), RARB (−3.218), and RASSF1A (−2.873). Another 11 showed moderate evidence: IL8 (−2.333), IL1B (−2.330), DCC (−2.245), SAT (−2.171), MINT31 (−2.009), CCNA1 (−1.956), p16 (−1.892), DAPK (−1.880), TGFBR2 (−1.745), MINT1 (−1.562), and MGMT (−1.534). Seven biomarkers only were supported by only weak evidence: HIC1 (−1.410), TIMP3 (−1.375), RBM6 (−1.256), PGP9.5 (−1.218), S100A2 (−1.123), CDH1 (−1.055), and CCND2 (−1.031). The 2 biomarkers lacking evidential support were miR31 and RIZ1.

Plots in [Figure 4](#fig4-1179299X17732007){ref-type="fig"} show the individual biomarkers and their associated confidence intervals by sensitivity and specificity with color coding for ES. Plot points were color coded according to ES: green = strong, gold = moderate, red = weak, and black = lacks evidence. The blue dots near the bottom right represent biomarkers with sensitivity over 0.75 and specificity over 0.75. The pink dots at lower right plots biomarkers with sensitivities over 0.75 or specificities over 0.75.

![Individual biomarker AUC plots coded by color for evidential support: green = strong evidence, gold = moderate, red = weak, black = lack of evidence Panels in bottom right illustrate 0.75 sensitivity *and* 0.75 specificity biomarkers (blue) and 0.75 sensitivity *or* 0.75 specificity biomarkers (pink) with their respective AUC's.](10.1177_1179299X17732007-fig4){#fig4-1179299X17732007}

Based on the summary variable estimates of n = 26, ES correlated moderately with LR, (Pearson *r* = .66) and PPV (*r* = .67). Area under the curve correlated with ES at (*r* = .52), LR (*r* = .29), and PPV (*r* = .42). Prevalence is not associated with ES but mildly with LR (−0.35).

Discussion {#section14-1179299X17732007}
==========

Detecting cancer early has life - and cost-saving advantages over treating advanced stages. Candidate cancer biomarkers are identified by differences in biomarker concentrations between healthy individuals and patients with OSCC. Four commonly derived indices of biomarkers---sensitivity, specificity, statistical significance, and AUC---do not yield a personal risk of disease---a key feature in the future of personalized medicine. To refine screening results to derive personal probability of disease, PPVs are the metric of choice.

Retrospective case-control methods artificially inflate prevalence and thus make it easier to overestimate efficiency in biomarker disease detection by inflating PPV estimates. LRs should be adjusted for exagerated high prevalences before estimating biomarker accuracy at lower disease prevalences.

In the final step after adjusting for prevalence, PPVs of biomarkers can be combined with other biomarkers in panels to be more informative with fewer biomarkers. Passing along positive test results from one biomarker to the next refines and augments information as to true disease status of a patient.

In all, 24 of 26 studied biomarkers demonstrated at least weak evidence for OSCC detection. The other 2 biomarkers indicated that their inclusion reduced PPV, ie, increased screening uncertainty. When weak and low information value biomarkers are eliminated the number required to screen will decrease, improving efficiency and affordability.

Area under the curve was an inferior metric as compared to LR in for achieving an acceptable PPV with fewer biomarkers. In [Figure 3](#fig3-1179299X17732007){ref-type="fig"}, when using the highest LR biomarkers first, AUC accuracy tops Bayesian accumulation and Youden index. Few biomarker's high performance measured by AUC is expected, since high AUC means high sensitivity and specificity. Such ideal biomarkers may act as initial screens for disease, but may not identify the disease for which the screening is intended. This finding illustrates Kraemer's assertion that more tests about a condition does not improve diagnostic and screening accuracy.^[@bibr14-1179299X17732007]^

Value of biomarker information {#section15-1179299X17732007}
------------------------------

Biomarker LR is a convenient expression of information value that can be manipulated mathematically to optimize biomarker usage. The number of biomarkers required to screen for a disease is a function of LR along with an estimated disease prevalence. When testing for life-threatening disease, the risk preference is to accept more false positives at the expense of false negatives.

The probability of having the disease given positive test results, PPV, is the ultimate objective of good medical tests. Biomarkers with both the highest sensitivity and specificity are the most accurate ones.^[@bibr14-1179299X17732007]^ Biomarkers are more informative when included in panels including other biomarkers with high LR that incrementally increase true positives and eliminate true negatives from the screening pool.^[@bibr16-1179299X17732007]^ High biomarker specificity appeared as more efficient than high sensitivity for screening.

Both AUC and Youden's index are hard to interpret and do not improve accuracy with additional biomarkers ([Figure 3](#fig3-1179299X17732007){ref-type="fig"}).

When screening a population where disease prevalence is unknown, prevalence might be estimated from groups with similar genetic predispositions, behavioral and dietary risks, cultural risks such as chewing betel nut, tobacco use, alcohol consumption, and other health habits and beliefs.

Interestingly, the most informative biomarkers (ones with the highest LR) turned out to have the highest specificities. Mathematically, this can be explained as the denominator of the LR---the proportion of false positives, or 1--specificity. Large specificities reduce the denominator and increase the overall LR.

The method of ES, where diagnostic accuracy with a biomarker is compared to accuracy without it, appears to ignore some promising biomarkers shown in [Figure 4](#fig4-1179299X17732007){ref-type="fig"}. CCND2, HIC1, PGP9.5, TGFBR2, and TIMP3 have more consistent grouping of data points and therefore are more reliable estimates of their AUC. However, since none of their regression lines pull towards the upper left-hand corner of high accuracy, such biomarkers are reliable but not accurate. They may be used alone or in combinations with others to achieve the best accuracy per unit costs of deployment, preservation, and transportation.

Limitations of method {#section16-1179299X17732007}
---------------------

The estimated LR of biomarkers in panels was probably diluted by other biomarkers also in the panel. If so, then we may expect biomarker accuracy to be lower than that estimated for single biomarkers in isolation. Nonetheless, biomarkers may interact synergistically in their ability to detect disease in which cases the simultaneous presence of such biomarkers has a higher LR than that expected from each individual one.

Where physicians, patients, and public health officials have budgetary constraints for biomarkers in field settings, the number of biomarkers required for screening may be reduced by obtaining a more focused at-risk population by first screening for behaviors and family history. The risk of making errors as false negatives versus false positives must always be balanced.

Data used herein were limited to studies published through 2014. Data collection ended in 2014 so that the method could be developed without introducing new information. Information published since then may update findings and be useful to test the method.

Some biomarkers tested are conceptually too general and will not serve to identify a specific disease. The ESR is one of those biomarkers. Elevated ESR might serve as a first-level general biomarker screen to be passed along to other biomarkers for more information. Elevated ESR indicates many diseases, not just cancer. Thus, ESR's strong ES and high sensitivity may make it ideal for ruling out cancer with a negative ESR result.

Finally, assays that came from the same authors or same labs must be considered as sources of bias. One paper^[@bibr63-1179299X17732007]^ reported all the CCND2 biomarker results, and perhaps a single laboratory was responsible for all CCND2 analyses. If so, a bias must be ruled out in future studies.

Conclusions {#section17-1179299X17732007}
===========

The same diagnostic and screening information may be obtained from fewer but more informative biomarkers rather than many weak to moderately informative ones.

By converting summary salivary biomarker data to positive likelihood ratios and then reading them as conditional probabilities ordered from highest to lowest LR, higher efficiency of OSCC screening may be obtained with fewer biomarkers. Sensitivity, specificity, and AUC do not allow the aggregation and ordering needed to improve screening accuracy.

The future and promise of personalized medicine is exactly the problem tackled here---how to translate multiple indicators of population-level disease and personal characteristics into a particular patient's probability of disease? Individual patient test results can then inform treatment and prevention strategies in the context of culture, behaviors, genetic predispositions, and economic and caretaker burdens.
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All biomarker panels culled from 16 evidence summary papers.

![](10.1177_1179299X17732007-table2)

  Biomarker panel                                                                                                           Reference Number   Number of patients with OSCC   Number of patients without OSCC   Total patients   TP    FP    FN    TN    Sensitivity              Specificity              LR+
  ------------------------------------------------------------------------------------------------------------------------- ------------------ ------------------------------ --------------------------------- ---------------- ----- ----- ----- ----- ------------------------ ------------------------ --------
  ADCYAP1_P455_R + CEBPA_P706_F + EPHA5_E158_R + FGF3\_ E198_R + HLF_E192_F + IL11_P11_R + INSR_P1063_R + NOTCH3\_ E403_F   37                 13                             10                                23               9     0     4     10    0.690 (0.562 to 0.818)   0.960 (0.898 to 1.00)    17.250
  AIM1                                                                                                                      63                 23                             73                                96               1     1     22    72    0.044 (0.001 to 0.220)   0.986 (0.926 to 1.00)    3.143
  AIM1                                                                                                                      63                 10                             41                                51               1     0     9     41    0.100 (0.003 to 0.445)   0.990 (0.930 to 1.00)    10.000
  AIM1                                                                                                                      63                 77                             41                                118              18    0     59    41    0.234 (0.145 to 0.344)   0.990 (0.930 to 1.00)    23.400
  AIM1                                                                                                                      63                 77                             73                                150              18    1     59    72    0.234 (0.145 to 0.344)   0.986 (0.926 to 1.00)    16.714
  CALCA                                                                                                                     63                 35                             20                                55               35    15    0     5     1.000 (0.918 to 1.000)   0.250 (0.087 to 0.491)   1.333
  CALCA                                                                                                                     63                 35                             30                                65               35    28    0     2     1.000 (0.918 to 1.000)   0.067 (0.008 to 0.221)   1.072
  CCNA1                                                                                                                     63                 24                             104                               128              0     0     24    104   0.000 (0.000 to 0.117)   0.990 (0.972 to 1.00)    0.000
  CCNA1                                                                                                                     63                 175                            444                               619              35    13    140   431   0.200 (0.143 to 0.267)   0.971 (0.951 to 0.984)   6.897
  CCNA1                                                                                                                     63                 102                            444                               546              63    13    39    431   0.618 (0.516 to 0.712)   0.971 (0.951 to 0.984)   21.310
  CCNA1                                                                                                                     63                 35                             284                               319              24    5     11    279   0.686 (0.516 to 0.712)   0.982 (0.972 to 1.00)    38.111
  CCNA1 + DCC + DAPK + MINT31 + p16                                                                                         33                 211                            527                               738              72    43    139   484   0.341 (0.308 to 0.374)   0.918 (0.630 to 1.00)    4.159
  CCNA1 + DAPK                                                                                                              63                 176                            416                               592              49    30    127   386   0.278 (0.214 to 0.351)   0.928 (0.889 to 0.951)   3.861
  CCNA1 + DAPK + p16                                                                                                        63                 176                            416                               592              52    30    124   386   0.295 (0.229 tp 0.369)   0.928 (0.889 to 0.951)   4.097
  CCNA1 + DCC                                                                                                               63                 175                            444                               619              45    18    130   426   0.257 (0.194 to 0.329)   0.959 (0.937 to 0.976)   6.268
  CCNA1 + DCC + DAPK                                                                                                        63                 176                            417                               593              56    34    120   383   0.318 (0.250 to 0.393)   0.918 (0.888 to 0.943)   3.878
  CCNA1 + DCC + DAPK + p16                                                                                                  63                 176                            417                               593              59    34    117   383   0.335 (0.266 to 0.410)   0.918 (0.888 to 0.943)   4.085
  CCNA1 + DCC + p16                                                                                                         63                 175                            444                               619              49    18    126   426   0.280 (0.215 to 0.353)   0.959 (0.937 to 0.976)   6.829
  CCNA1 + p16                                                                                                               63                 175                            444                               619              39    13    136   431   0.223 (0.164 to 0.292)   0.971 (0.951 to 0.984)   7.690
  CCND2                                                                                                                     63                 47                             284                               331              3     5     44    279   0.064 (0.013 to 0.175)   0.982 (0.959 to 0.994)   3.556
  CCND2                                                                                                                     63                 136                            97                                233              10    10    126   87    0.074 (0.036 to 0.131)   0.897 (0.819 to 0.949)   0.718
  CCND2                                                                                                                     63                 35                             97                                132              24    10    11    87    0.686 (0.507 to 0.832)   0.897 (0.819 to 0.947)   6.660
  CCND2                                                                                                                     63                 35                             284                               319              24    5     11    279   0.686 (0.507 to 0.832)   0.982 (0.959 to 0.994)   38.111
  CCND2 + HIC1                                                                                                              63                 49                             248                               297              22    32    27    216   0.449 (0.307 to 0.598)   0.871 (0.823 to 0.910)   3.481
  CCND2 + HIC1 + PGP9.5                                                                                                     63                 42                             189                               231              22    36    20    153   0.524 (0.364 to 0.680)   0.810 (0.746 to 0.863)   2.758
  CCND2 + TGFBR2 + TIMP3 + HIC1 + PGP9.5                                                                                    63                 36                             130                               166              26    56    10    74    0.722 (0.548 to 0.858)   0.569 (0.480 to 0.656)   1.675
  CCND2 + TGFBR2 +TIMP3 + HIC1                                                                                              63                 40                             126                               166              26    52    14    74    0.650 (0.483 to 0.794)   0.587 (0.496 to 0.674)   1.574
  CCND2 + TGFRB2 + HIC1 + PGP9.5                                                                                            63                 37                             117                               154              22    41    15    76    0.595 (0.421 to 0.753)   0.650 (0.556 to 0.736)   1.700
  CCND2 + TIMP3 + HIC1                                                                                                      63                 46                             178                               224              26    47    20    131   0.565 (0.411 to 0.711)   0.736 (0.665 to 0.799)   2.140
  CCND2 + TIMP3 + HIC1 + PGP9.5                                                                                             63                 40                             182                               222              26    51    14    131   0.650 (0.483 to 0.794)   0.720 (0.649 to 0.784)   2.321
  CDH1                                                                                                                      63                 66                             116                               182              20    72    46    44    0.303 (0.196 to 0.429)   0.379 (0.291 to 0.474)   0.488
  CDH1                                                                                                                      63                 62                             320                               382              20    86    42    234   0.323 (0.209 to 0.453)   0.731 (0.679 to 0.779)   1.201
  CDH1                                                                                                                      63                 77                             116                               193              70    72    7     44    0.909 (0.822 to 0.963)   0.379 (0.291 to 0.474)   1.464
  CDH1                                                                                                                      63                 77                             320                               397              70    86    7     234   0.909 (0.822 to 0.963)   0.731 (0.679 to 0.779)   3.379
  CDH1 + CCND2 + HIC1 + PGP9.5                                                                                              63                 39                             217                               256              30    110   9     107   0.769 (0.607 to 0.889)   0.493 (0.425 to 0.562)   1.517
  CDH1 + CCND2 + TIMP3 + HIC1 + PGP9.5                                                                                      63                 39                             208                               247              34    120   5     88    0.872 (0.726 to 0.957)   0.423 (0.355 to 0.493)   1.511
  CDH1 + TIMP3 + HIC1                                                                                                       63                 49                             267                               316              34    114   15    153   0.694 (0.546 to 0.818)   0.573 (0.511 to 0.633)   1.625
  CDH1 + TIMP3 + HIC1 + PGP9.5                                                                                              63                 42                             209                               251              34    118   8     91    0.810 (0.659 to 0.914)   0.435 (0.367 to 0.506)   1.434
  DAPK                                                                                                                      63                 176                            451                               627              28    17    148   434   0.159 (0.108 to 0.222)   0.962 (0.940 to 0.978)   4.184
  DAPK                                                                                                                      63                 136                            451                               587              102   17    34    434   0.750 (0.669 to 0.820)   0.962 (0.940 to 0.978)   19.737
  DCC                                                                                                                       63                 27                             135                               162              0     0     27    135   0.000 (0.000 to 0.105)   0.990 (0.978 to 1.00)    0.000
  DCC                                                                                                                       63                 176                            462                               638              21    5     155   457   0.119 (0.075 to 0.177)   0.989 (0.975 to 0.997)   10.818
  DCC                                                                                                                       63                 135                            135                               270              105   0     30    135   0.778 (0.698 to 0.845)   0.990 (0.978 to 1.00)    77.800
  DCC                                                                                                                       63                 135                            462                               597              105   5     30    457   0.778 (0.698 to 0.845)   0.989 (0.975 to 0.997)   70.727
  DCC + DAPK + p16                                                                                                          63                 176                            422                               598              43    21    133   401   0.244 (0.183 to 0.315)   0.950 (0.925 to 0.969)   4.880
  EDNRB                                                                                                                     58                 161                            30                                191              105   15    56    15    0.650 (0.612 to 0.688)   0.510 (0.419 to 0.601)   1.327
  ERBB4_P255_F + IL11_P11_R + PTCH2_P37_F + TMEFF1_P234_F + TNFSF10_E53_F + TWIST1_P44_R                                    37                 13                             10                                23               8     0     5     10    0.620 (0.485 to 0.755)   0.990 (0.959 to 1.00)    62.000
  ESR                                                                                                                       63                 33                             119                               152              1     2     32    117   0.030 (0.001 to 0.158)   0.983 (0.941 to 0.998)   1.765
  ESR                                                                                                                       63                 16                             20                                36               1     0     15    20    0.063 (0.002 to 0.302)   0.990 (0.861 to 1.00)    6.300
  ESR                                                                                                                       63                 35                             20                                55               21    0     14    20    0.600 (0.421 to 0.761)   0.990 (0.861 to 1.00)    60.000
  ESR                                                                                                                       63                 35                             119                               154              21    2     14    117   0.600 (0.421 to 0.761)   0.983 (0.941 to 0.998)   35.294
  GABRB3_E42_F + IL11_P11_R + INSR_P1063_R + NOTCH3_E403_F + NTRK3_E131_F + PXN_P308_F                                      37                 13                             10                                23               10    2     3     8     0.770 (0.653 to 0.887)   0.830 (0.711 to 0.949)   4.529
  HIC1                                                                                                                      63                 70                             373                               443              22    28    48    345   0.314 (0.209 to 0.436)   0.925 (0.893 to 0.950)   4.187
  HIC1                                                                                                                      63                 45                             46                                91               45    40    0     6     1.000 (0.936 to 1.000)   0.130 (0.049 to 0.263)   1.149
  HIC1                                                                                                                      63                 45                             373                               418              45    28    0     345   1.000 (0.936 to 1.000)   0.925 (0.893 to 0.950)   13.333
  HIC1 + PGP9.5                                                                                                             63                 57                             202                               259              22    32    35    170   0.386 (0.260 to 0.524)   0.842 (0.784 to 0.889)   2.443
  HOXA9                                                                                                                     67                 4                              4                                 8                3     0     1     4     0.680 (0.447 to 0.913)   0.990 (0.940 to 1.00)    68.000
  HOXA9 + NID2                                                                                                              67                 4                              4                                 8                4     0     0     4     0.940 (0.821 to 1.00)    0.970 (0.885 to 1.00)    31.333
  IL-1B + IL-8 + M2BP                                                                                                       62                 35                             51                                86               31    11    4     40    0.890 (0.837 to 0.943)   0.780 (0.722 to 0.838)   4.045
  IL-8                                                                                                                      23                 19                             32                                51               16    1     3     31    0.860 (0.780 to 0.940)   0.970 (0.940 to 1.00)    28.667
  IL-8 + IL-1B + SAT + S100P                                                                                                6,8                35                             51                                86               24    2     12    49    0.670 (0.591 to 0.749)   0.960 (0.705 to 1.00)    16.750
  IL8 + IL1B + OAZ1 + SAT                                                                                                   22                 32                             32                                64               29    3     3     29    0.910 (0.859 to 0.961)   0.910 (0.601 to 1.00)    10.111
  IL8 + IL1B + SAT + DUSP1                                                                                                  74 \[cohort 3\]    30                             30                                60               24    7     6     23    0.800 (0.727 to 0.873)   0.770 (0.276 to 1.00)    3.478
  IL8 + IL1B + SAT + OAZ1                                                                                                   74 \[cohort 5\]    31                             70                                101              14    17    17    53    0.450 (0.361 to 0.539)   0.760 (0.049 tp 1.00)    1.875
  IL8 + IL1B + SAT + OAZ1                                                                                                   74 \[cohort 4\]    36                             54                                90               23    14    13    41    0.640 (0.560 to 0.720)   0.750 (0.171 to 1.00)    2.560
  IL8 + IL1B + SAT + OAZ1                                                                                                   74 \[cohort 1\]    48                             48                                96               34    13    14    35    0.700 (0.634 to 0.766)   0.720 (0.156 to 1.00)    2.500
  IL8 + IL1B + SAT + OAZ1                                                                                                   74 \[cohort 3\]    30                             30                                60               22    8     8     22    0.730 (0.649 to 0.811)   0.730 (0.179 to 1.00)    2.704
  IL8 + IL1B + SAT + OAZ1                                                                                                   74 \[cohort 2\]    24                             24                                48               19    6     5     19    0.790 (0.707 to 0.873)   0.770 (0.269 to 1.00)    3.435
  IL8 + SAT + H3F3A + S100P                                                                                                 74 \[cohort 1\]    48                             48                                96               34    5     14    43    0.710 (0.645 to 0.775)   0.890 (0.500 to 1.00)    6.455
  IL8 + SAT + OAZ1 + S100P                                                                                                  74 \[cohort 5\]    31                             70                                101              27    31    4     39    0.870 (0.810 to 0.930)   0.560 (0.008 to 1.00)    1.977
  IL8+IL1B+S100P+OAZ1                                                                                                       74 \[cohort 4\]    36                             54                                90               23    8     13    46    0.640 (0.560 to 0.720)   0.860 (0.813 to 0.907)   4.571
  M2BP + profilin + CD59 + MRP14 + catalase                                                                                 34                 64                             64                                128              58    11    6     53    0.900 (0.863 to 0.938)   0.830 (0.783 to 0.877)   5.294
  MGMT                                                                                                                      63                 149                            239                               388              20    12    129   227   0.134 (0.084 to 0.200)   0.950 (0.914 to 0.974)   2.680
  MGMT                                                                                                                      63                 44                             239                               283              10    12    34    227   0.227 (0.115 to 0.378)   0.950 (0.914 to 0.974)   4.540
  MGMT + CCNA1                                                                                                              63                 150                            240                               390              50    24    100   216   0.333 (0.259 to 0.415)   0.900 (0.855 to 0.935)   3.330
  MGMT + CCNA1 + p16                                                                                                        63                 151                            240                               391              51    24    100   216   0.338 (0.263 to 0.419)   0.900 (0.855 to 0.935)   3.380
  MINT1                                                                                                                     63                 131                            296                               427              46    100   85    196   0.351 (0.270 to 0.439)   0.662 (0.605 to 0.716)   1.038
  MINT1                                                                                                                     63                 87                             19                                106              79    6     8     13    0.908 (0.827 to 0.960)   0.684 (0.435 to 0.874)   2.873
  MINT1                                                                                                                     63                 87                             296                               383              79    100   8     196   0.908 (0.827 to 0.960)   0.662 (0.605 to 0.716)   2.686
  MINT31                                                                                                                    63                 28                             42                                70               0     0     28    42    0.000 (0.000 to 0.102)   0.990 (0.931 to 1.00)    0.000
  MINT31                                                                                                                    63                 175                            492                               667              8     0     167   492   0.046 (0.020 to 0.088)   0.990 (0.994 to 1.00)    4.600
  MINT31                                                                                                                    63                 136                            42                                178              50    0     86    42    0.368 (0.287 to 0.455)   0.990 (0.931 to 1.00)    36.800
  MINT31                                                                                                                    63                 136                            492                               628              50    0     86    492   0.368 (0.287 to 0.455)   0.990 (0.994 to 1.00)    36.800
  MINT31 + CCNA1                                                                                                            63                 174                            444                               618              39    13    135   431   0.224 (0.165 to 0.293)   0.971 (0.951 to 0.984)   7.724
  MINT31 + CCNA1 + DAPK                                                                                                     63                 175                            416                               591              52    30    123   386   0.297 (0.231 to 0.371)   0.928 (0.889 to 0.951)   4.125
  MINT31 + CCNA1 + DAPK + p16                                                                                               63                 176                            416                               592              54    30    122   386   0.307 (0.240 to 0.381)   0.928 (0.889 to 0.951)   4.264
  MINT31 + CCNA1 + DCC                                                                                                      63                 174                            444                               618              47    18    127   426   0.270 (0.206 to 0.343)   0.959 (0.937 to 0.976)   6.585
  MINT31 + CCNA1 + DCC + DAPK                                                                                               63                 175                            417                               592              58    34    117   383   0.331 (0.262 to 0.406)   0.918 (0.888 to 0.943)   4.037
  MINT31 + CCNA1 + p16                                                                                                      63                 175                            444                               619              42    13    133   431   0.240 (0.179 to 0.310)   0.971 (0.951 to 0.984)   8.276
  MINT31 + CCNA1 + p16                                                                                                      50                 33                             61                                94               8     2     25    59    0.240 (0.166 to 0.314)   0.971 (0.610 to 1.00)    8.276
  MINT31 + DCC + DAPK + p16                                                                                                 63                 176                            422                               598              44    21    132   401   0.250 (0.188 to 0.321)   0.950 (0.925 to 0.969)   5.000
  MINT31 + MGMT + CCNA1                                                                                                     63                 150                            240                               390              52    24    98    216   0.347 (0.271 to 0.429)   0.900 (0.855 to 0.935)   3.470
  MINT31 + MGMT + CCNA1 + p16                                                                                               63                 151                            240                               391              53    24    98    216   0.351 (0.275 to 0.433)   0.900 (0.855 to 0.935)   3.510
  MINT31 +CCNA1 + DCC + DAPK + p16                                                                                          63                 176                            417                               593              60    34    116   383   0.341 (0.271 to 0.416)   0.918 (0.888 to 0.943)   4.159
  MINT31 +CCNA1 + DCC +p16                                                                                                  63                 175                            444                               619              50    18    125   426   0.286 (0.220 to 0.359)   0.959 (0.937 to 0.976)   6.976
  miR-125a + miR-200a                                                                                                       44                 50                             50                                100              NA    NA    NA    NA    0.910 (0.870 to 0.950)   0.910 (0.870 to 0.950)   NA
  miR-31                                                                                                                    78                 45                             24                                69               36    8     9     16    0.800 (0.740 to 0.860)   0.680 (0.585 to 0.775)   2.500
  p16                                                                                                                       63                 39                             102                               141              0     0     39    102   0.000 (0.000 to 0.074)   0.990 (0.971 to 1.00)    0.000
  p16                                                                                                                       63                 177                            500                               677              8     0     169   500   0.045 (0.020 to 0.087)   0.990 (0.994 to 1.00)    4.500
  p16                                                                                                                       63                 136                            102                               238              18    0     118   102   0.132 (0.080 to 0.201)   0.990 (0.971 to 1.00)    13.200
  p16                                                                                                                       63                 136                            500                               636              18    0     118   500   0.132 (0.080 to 0.201)   0.990 (0.994 to 1.00)    13.200
  PGP9.5                                                                                                                    63                 52                             203                               255              4     5     48    198   0.077 (0.021 to 0.185)   0.975 (0.944 to 0.992)   3.080
  PGP9.5                                                                                                                    63                 34                             112                               146              28    78    6     34    0.824 (0.655 to 0.932)   0.304 (0.220 to 0.398)   1.184
  PGP9.5                                                                                                                    63                 45                             112                               157              41    78    4     34    0.911 (0.788 to 0.975)   0.304 (0.220 to 0.398)   1.309
  PGP9.5                                                                                                                    63                 45                             203                               248              41    5     4     198   0.911 (0.788 to 0.975)   0.975 (0.944 to 0.992)   36.440
  Prevalence screen HOXA9                                                                                                   67,66              4                              4                                 8                3     0     1     4     0.850 (0.671 to 1.00)    0.970 (0.885 to 1.00)    28.333
  RARB                                                                                                                      63                 13                             85                                98               0     0     13    85    0.000 (0.000 to 0.206)   0.990 (0.956 to 1.00)    0.000
  RARB                                                                                                                      63                 44                             35                                79               35    17    9     18    0.796 (0.647 to 0.902)   0.514 (0.340 to 0.686)   1.638
  RARB                                                                                                                      63                 44                             85                                129              35    0     9     85    0.796 (0.647 to 0.902)   0.990 (0.965 to 1.00)    79.600
  RASSF1A                                                                                                                   63                 44                             35                                79               5     0     39    35    0.114 (0.038 to 0.246)   0.990 (0.918 to 1.00)    11.400
  RASSF1A                                                                                                                   63                 44                             104                               148              5     1     39    103   0.114 (0.038 to 0.246)   0.990 (0.948 to 1.00)    11.400
  RBM6                                                                                                                      63                 44                             18                                62               43    14    1     4     0.977 (0.880 to 1.000)   0.222 (0.064 to 0.476)   1.256
  RBM6                                                                                                                      63                 44                             35                                79               43    35    1     0     0.977 (0.880 to 1.000)   0.000 (0.000 to 0.082)   0.977
  RIZ1                                                                                                                      63                 44                             18                                62               3     0     41    18    0.068 (0.014 to 0.187)   0.990 (0.847 to 1.00)    6.800
  RIZ1                                                                                                                      63                 44                             35                                79               3     4     41    31    0.068 (0.014 to 0.187)   0.886 (0.733 to 0.968)   0.596
  S100A2                                                                                                                    63                 44                             12                                56               42    10    2     2     0.955 (0.845 to 0.994)   0.167 (0.021 to 0.484)   1.146
  S100A2                                                                                                                    63                 44                             35                                79               42    31    2     4     0.955 (0.845 to 0.994)   0.114 (0.032 to 0.267)   1.078
  saliva HOXA9                                                                                                              67,66              4                              4                                 8                3     2     1     2     0.750 (0.533 to 0.967)   0.530 (0.280 to 0.780)   1.596
  saliva NID2                                                                                                               67,66              4                              4                                 8                4     3     1     1     0.870 (0.702 to 1.00)    0.210 (0.006 to 0.414)   1.101
  TGFBR2                                                                                                                    63                 37                             134                               171              3     8     34    126   0.081 (0.017 to 0.219)   0.940 (0.886 to 0.974)   1.350
  TGFBR2                                                                                                                    63                 11                             44                                55               6     33    5     11    0.546 (0.234 to 0.833)   0.250 (0.132 to 0.403)   0.728
  TGFBR2                                                                                                                    63                 42                             134                               176              37    8     5     126   0.881 (0.744 to 0.960)   0.940 (0.886 to 0.974)   14.683
  TGFBR2 + HIC1                                                                                                             63                 44                             149                               193              22    35    22    114   0.500 (0.346 to 0.654)   0.765 (0.689 to 0.831)   2.128
  TGFBR2 + HIC1 + PGP9.5                                                                                                    63                 39                             118                               157              22    39    17    79    0.564 (0.386 to 0.722)   0.669 (0.577 to 0.753)   1.704
  TGFBR2 + TIMP3 + HIC1                                                                                                     63                 43                             158                               201              26    50    17    108   0.605 (0.444 to 0.750)   0.684 (0.605 to 0.755)   1.915
  TGFBR2 + TIMP3 + HIC1 + PGP9.5                                                                                            63                 38                             131                               169              26    54    12    77    0.684 (0.514 to 0.825)   0.588 (0.499 to 0.673)   1.660
  TIMP3                                                                                                                     63                 50                             296                               346              5     16    45    280   0.100 (0.033 to 0.218)   0.946 (0.914 to 0.969)   1.852
  TIMP3                                                                                                                     63                 176                            450                               626              20    32    156   418   0.114 (0.071 to 0.170)   0.929 (0.901 to 0.951)   1.606
  TIMP3                                                                                                                     63                 138                            296                               434              102   16    36    280   0.739 (0.658 to 0.810)   0.946 (0.914 to 0.969)   13.685
  TIMP3                                                                                                                     63                 138                            450                               588              102   32    36    418   0.739 (0.658 to 0.810)   0.929 (0.901 to 0.951)   10.408
  TIMP3 + HIC1                                                                                                              63                 52                             278                               330              26    43    26    235   0.500 (0.358 to 0.642)   0.845 (0.797 to 0.886)   3.226
  TIMP3 + HIC1 + PGP9.5                                                                                                     63                 45                             183                               228              26    47    19    136   0.578 (0.422 to 0.723)   0.743 (0.674 to 0.805)   2.249
  Valine + lactic acid                                                                                                      72                 37                             32                                69               32    6     5     26    0.865 (0.809 to 0.921)   0.824 (0.757 to 0.891)   4.915
